New Stock News | Ding Tai Pharmaceutical Submits Again to Hong Kong Stock Exchange.

06:20 16/06/2026

According to the disclosure of the Hong Kong Stock Exchange on June 15th, Jiangsu Dingtai Pharmaceutical Research Co., Ltd. (referred to as Dingtai Pharmaceutical) submitted an application to the main board of the Hong Kong Stock Exchange, with Citi and Haitong International as joint sponsors.

According to the disclosure of the Hong Kong Stock Exchange on June 15, Jiangsu Dingtai Pharmaceutical Research Co., Ltd. (referred to as Dingtai Pharmaceutical) has submitted an application to the main board of the Hong Kong Stock Exchange, with Citigroup and Haitong International as joint sponsors. The company had previously submitted an IPO application to the Hong Kong Stock Exchange on October 31, 2025. According to the prospectus, Dingtai Pharmaceutical is a new type of Contract Research Organization (CRO) dedicated to providing globally integrated solutions based on disease biology for pharmaceutical companies and research institutions. According to data from Frost & Sullivan, based on revenue in 2025, the company is the largest CRO in the field of non-clinical research in cardiovascular metabolic diseases in China.

Jack Technology (603337.SH) granted 670.33 million restricted stocks to 302 incentive recipients.

Pointing the lifeblood of AI storage! Netlist (NLST.US) upgrades in the face of Samsung's patent battle, HBM and DDR5 may face US import ban.

HK Stock Market Move | ANDRE JUICE(02218) plunged nearly 20% during trading. The Shanghai Stock Exchange has issued a regulatory letter regarding the abnormal fluctuations in Yantai North Andre Juice's stock.

Jack Technology (603337.SH) granted 670.33 million restricted stocks to 302 incentive recipients.

Pointing the lifeblood of AI storage! Netlist (NLST.US) upgrades in the face of Samsung's patent battle, HBM and DDR5 may face US import ban.